These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 12628848)

  • 1. Predicting the maximum-tolerated dose of PNU-159548 (4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin) in humans using CFU-GM clonogenic assays and prospective validation.
    Moneta D; Geroni C; Valota O; Grossi P; de Jonge MJ; Brughera M; Colajori E; Ghielmini M; Sessa C
    Eur J Cancer; 2003 Mar; 39(5):675-83. PubMed ID: 12628848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I and pharmacokinetic studies of PNU-159548, a novel alkycycline, administered intravenously to patients with advanced solid tumours.
    de Jonge MJ; Verweij J; van der Gaast A; Valota O; Mora O; Planting AS; Mantel MA; Bosch SV; Lechuga MJ; Fiorentini F; Hess D; Sessa C
    Eur J Cancer; 2002 Dec; 38(18):2407-15. PubMed ID: 12460785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological and toxicological aspects of 4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548): a novel antineoplastic agent.
    Geroni C; Ripamonti M; Arrigoni C; Fiorentini F; Capolongo L; Moneta D; Marchini S; Della Torre P; Albanese C; Lamparelli MG; Ciomei M; Rossi R; Caruso M
    Cancer Res; 2001 Mar; 61(5):1983-90. PubMed ID: 11280756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myelotoxic effects of the bifunctional alkylating agent bizelesin on human, canine and murine myeloid progenitor cells.
    Volpe DA; Tomaszewski JE; Parchment RE; Garg A; Flora KP; Murphy MJ; Grieshaber CK
    Cancer Chemother Pharmacol; 1996; 39(1-2):143-9. PubMed ID: 8995512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I clinical and pharmacological study of oral methoxymorpholinyl doxorubicin (PNU 152243).
    Sessa C; Zucchetti M; Ghielmini M; Bauer J; D'Incalci M; de Jong J; Naegele H; Rossi S; Pacciarini MA; Domenigoni L; Cavalli F
    Cancer Chemother Pharmacol; 1999; 44(5):403-10. PubMed ID: 10501914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalidation of the rat CFU-GM assay for in vitro toxicology applications.
    Pessina A; Bonomi A; Cavicchini L; Albella B; Cerrato L; Parent-Massin D; Sibiril Y; Parchment R; Behrsing H; Verderio P; Pizzamiglio S; Giangreco M; Baglio C; Coccè V; Sisto F; Gribaldo L
    Altern Lab Anim; 2010 May; 38(2):105-17. PubMed ID: 20507183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 4-Demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548), a novel anticancer agent active against tumor cell lines with different resistance mechanisms.
    Marchini S; Damia G; Broggini M; Pennella G; Ripamonti M; Marsiglio A; Geroni C
    Cancer Res; 2001 Mar; 61(5):1991-5. PubMed ID: 11280757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 4-Demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548): a promising new candidate for chemotherapeutic treatment of osteosarcoma patients.
    Pasello M; Hattinger CM; Stoico G; Manara MC; Benini S; Geroni C; Mercuri M; Scotlandi K; Picci P; Serra M
    Eur J Cancer; 2005 Sep; 41(14):2184-95. PubMed ID: 16140527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of the CFU-GM assay to predict acute drug-induced neutropenia: an international blind trial to validate a prediction model for the maximum tolerated dose (MTD) of myelosuppressive xenobiotics.
    Pessina A; Albella B; Bayo M; Bueren J; Brantom P; Casati S; Croera C; Gagliardi G; Foti P; Parchment R; Parent-Massin D; Schoeters G; Sibiril Y; Van Den Heuvel R; Gribaldo L
    Toxicol Sci; 2003 Oct; 75(2):355-67. PubMed ID: 12883091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of CFU-GM assay for prediction of human maximum tolerated dose of a new antitumoral drug: Yondelis (ET-743).
    Gómez SG; Bueren JA; Faircloth G; Albella B
    Toxicol In Vitro; 2003; 17(5-6):671-4. PubMed ID: 14599461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalidation of a model for predicting acute neutropenia by colony forming unit granulocyte/macrophage (CFU-GM) assay.
    Pessina A; Albella B; Bueren J; Brantom P; Casati S; Gribaldo L; Croera C; Gagliardi G; Foti P; Parchment R; Parent-Massin D; Sibiril Y; Van Den Heuvel R
    Toxicol In Vitro; 2001 Dec; 15(6):729-40. PubMed ID: 11698175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk assessment of human myelotoxicity of anticancer drugs: a predictive model and the in vitro colony forming unit granulocyte/macrophage (CFU-GM) assay.
    Masubuchi N
    Pharmazie; 2006 Feb; 61(2):135-9. PubMed ID: 16526561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicity of idarubicin and doxorubicin towards normal and leukemic human bone marrow progenitors in relation to their proliferative state.
    Minderman H; Linssen P; van der Lely N; Wessels J; Boezeman J; de Witte T; Haanen C
    Leukemia; 1994 Mar; 8(3):382-7. PubMed ID: 8127143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro toxicity of ET-743 and aplidine, two marine-derived antineoplastics, on human bone marrow haematopoietic progenitors. comparison with the clinical results.
    Albella B; Faircloth G; López-Lázaro L; Guzmán C; Jimeno J; Bueren JA
    Eur J Cancer; 2002 Jul; 38(10):1395-404. PubMed ID: 12091072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of the Cdk-inhibitor roscovitine on mouse hematopoietic progenitors in vivo and in vitro.
    Song H; Vita M; Sallam H; Tehranchi R; Nilsson C; Sidén A; Hassan Z
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):841-9. PubMed ID: 17318617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential toxicity of camptothecin, topotecan and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitro.
    Erickson-Miller CL; May RD; Tomaszewski J; Osborn B; Murphy MJ; Page JG; Parchment RE
    Cancer Chemother Pharmacol; 1997; 39(5):467-72. PubMed ID: 9054963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Idarubicinol myelotoxicity: a comparison of in vitro data with clinical outcome in patients treated with high-dose idarubicin.
    Corsini C; Ghielmini M; Mancuso P; Tealdo F; Paolucci M; Zucchetti M; Ferrucci PF; Cocorocchio E; Mezzetti M; Mori A; Riggi M; D'Incalci M; Martinelli G
    Br J Cancer; 2000 Feb; 82(3):524-8. PubMed ID: 10682659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Basic fibroblast growth factor (B-FGF) induces early- (CFU-s) and late-stage hematopoietic progenitor cell colony formation (CFU-gm, CFU-meg, and BFU-e) by synergizing with GM-CSF, Meg-CSF, and erythropoietin, and is a radioprotective agent in vitro.
    Gallicchio VS; Hughes NK; Hulette BC; DellaPuca R; Noblitt L
    Int J Cell Cloning; 1991 May; 9(3):220-32. PubMed ID: 2061622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients.
    Toffoli G; Sorio R; Aita P; Crivellari D; Corona G; Bearz A; Robieux I; Colussi AM; Stocco F; Boiocchi M
    Clin Cancer Res; 2000 Jun; 6(6):2279-87. PubMed ID: 10873078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A predictive model of human myelotoxicity using five camptothecin derivatives and the in vitro colony-forming unit granulocyte/macrophage assay.
    Masubuchi N; May RD; Atsumi R
    Clin Cancer Res; 2004 Oct; 10(19):6722-31. PubMed ID: 15475463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.